Tuesday - March 24, 2026
Tecvayli Monotherapy Application Submitted to the EMA for Relapsed/refractory Multiple Myeloma After at Least One Prior Therapy
March 11, 2026
RARITAN, New Jersey, March 11 -- Johnson and Johnson Innovative Medicine issued the following news release on March 10, 2026:

* * *

TECVAYLI(R)/ (teclistamab) monotherapy application submitted to the EMA for relapsed/refractory multiple myeloma after at least one prior therapy

Application supported by Phase 3 data reinforcing teclistamab regimens as a potential standard of care after at least one prior therapy/1

Teclistamab monotherapy delivere . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products